We are testing a new medication, EPX-100, to see if it helps children and adults with Dravet Syndrome manage their seizures better than a placebo. This study aims to find out if this treatment can be a useful addition to their current care.
Health conditions and diseases that the clinical trial is designed to study and treat.
Dravet syndrome is a rare and severe form of epilepsy that usually begins in the first year of life, characterized by frequent and prolonged seizures, developmental delays, and a higher risk of sudden unexpected death in epilepsy (SUDEP).
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
